Serge Bodart of IDDI provides insight on the pharma and biopharma trends impacting CROs, outsourcing in today’s market, and advances in clinical research.
Supports clinical trial continuity for biopharma companies during COVID-19 pandemic by transferring clinical trial patients to AES’ dedicated research sites
Clinical study will explore the potential of TJM2, a mAb against Cytokine Release Syndrome, which is an overreaction of the immune system caused by inflammation